Trial reportJournal of ovarian research2024
The impact of resveratrol on the outcome of the in vitro fertilization: an exploratory randomized placebo-controlled trial.
Trial report in Journal of ovarian research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Resveratrol and Female Fertility: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Resveratrol ameliorates mitochondrial biogenesis and reproductive outcomes in women with polycystic ovary syndrome undergoing assisted reproduction: a randomized, triple-blind, placebo-controlled clinical trial.Journal of ovarian research · 2024Trial
- Nutritional Regulation of Ovarian Bioenergetics: Implications for Reproductive Aging and Female Infertility.Nutrients · 2026Review
- 630 nm LED phototherapy enhances ovarian function and fertility potential in advanced reproductive age females.Bioengineering & translational medicine · 2026Article
- Therapeutic Roles and Safety Profiles of Non-Vitamin Antioxidant Supplements in Female Infertility: A Narrative Review.Journal of family & reproductive health · 2026Review
- Multi-target modulation of the homologous recombination pathway by resveratrol promotes DNA damage repair in POI: integrated network pharmacology, molecular dynamics simulation, and experimental validation.International journal of surgery (London, England) · 2026Article
- Reproductive aging in biological females: mechanisms and immediate consequences.Frontiers in endocrinology · 2025Review
- Plant-based bioactives and oxidative stress in reproduction: anti-inflammatory and metabolic protection mechanisms.Frontiers in nutrition · 2025Review
- Targeting programmed cell death with natural products: a potential therapeutic strategy for diminished ovarian reserve and fertility preservation.Frontiers in pharmacology · 2025Review
- Modulation of neuroinflammation by natural plant compounds: a promising approach for ischemic stroke.Frontiers in pharmacology · 2025Review
- Resveratrol and Extra Virgin Olive Oil: Protective Agents Against Age-Related Disease.Nutrients · 2024Review
- Electro-Metabolic Coupling of Cumulus-Oocyte Complex.International journal of molecular sciences · 2024Review
- Validation of the follicular and ovarian thresholds by an 18-MHz ultrasound imaging in polycystic ovary syndrome: a pilot cutoff for North African patients.Therapeutic advances in reproductive healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResveratrol is a natural polyphenolic compound present in plants and red wine with many potential health benefits. This compound has various anti-inflammatory and anti-tumor properties and can improve cellular mitochondrial activity. This trial was designed to evaluate the effect on the outcome of IVF of Resveratrol supplementation in women > 35 years with good ovarian reserve (AMH > 1.2 ng/ml). Women were randomized to receive or placebo or Resveratrol (150 mg per day) for three months preceding the ovarian stimulation (OS). All patients were stimulated with a starting dose of recombinant FSH ranging between 150 and 300 IU according to age and ovarian reserve. GnRH antagonist flexible protocol was adopted for pituitary suppression. Triggering was performed with urinary hCG (10.000 IU).
resultsThe study was conducted between January 2019 and December 2022 with aa total of 37 cases and 33 controls were recruited. No statistically significant differences in the number of oocytes retrieved, biochemical pregnancy, clinical pregnancy and live birth rates were observed between women treated with resveratrol and control group. A statistically significant increase in the follicle output rate (FORT) and follicle-to oocyte index (FOI) was observed in women treated with resveratrol-based nutraceutical (0.92 versus 0.77 [p = 0.02], and 0.77 versus 0.64 [p = 0.006], respectively).
conclusionsPreliminary results from this study indicate that pre-treatment with resveratrol may improve ovarian sensitivity to exogenous FSH, which in turn may decrease the risk of hypo-response to OS in advanced reproductive age women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.